Lance D. Miller, Ph.D.Wake Forest Baptist Health

Lance D. Miller, Ph.D.

Core Director,
Associate Professor,

Clinical Specialties

Cancer Cell Biology, Cancer Genetics, Breast Cancer

Contact Information

Academic: 336-716-6017 | Department: 336-716-6017


Media Medical Expert »

Education & Training

  • Ph.D., University of North Carolina-Chapel Hill , 2001
  • B.S., University of North Carolina-Chapel Hill , 1992
  • M.S., East Carolina University , 1995
Lance D. Miller, Ph.D.Wake Forest Baptist Health

Lance D. Miller, Ph.D.

Core Director, Comprehensive Cancer Center
Associate Professor, Cancer Biology
Comprehensive Cancer Center
Office of Women in Medicine and Science

Research Interests

cancer/oncogenesis, genetics/genome, genomics and proteomics, medical technology/devices

Contact Information

Academic: 336-716-6017 | Department: 336-716-6017


Media Medical Expert »

Recent Publications

Wang W, Deng Z, Hatcher H, Miller LD, Di X, Tesfay L, Sui G, D'Agostino RB Jr, Torti FM, Torti SV. IRP2 regulates breast tumor growth. Cancer Res. 2014;74(2):497-507.

Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, Wauthier E, Tajiri H, Miller LD, Wang XW, Reid LM, Nakauchi H. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology. 2013;57(4):1469-1483.

Wang W, Deng ZY, Hatcher H, Miller L, Di XM, Tesfay L, D'Agostino RB Jr, Torti S, Torti F. Irp2 regulates tumor growth in breast cancer [abstract]. Am J Hematol. 2013;88(5):E15.

Maglic D, Zhu S, Fry EA, Taneja P, Kai F, Kendig RD, Sugiyama T, Miller LD, Willingham MC, Inoue K. Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. Oncogene. 2013;32(35):4120-4129.

Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, Black MA, Miller LD. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol. 2013;14(4):R34.

Stovall DB, Wan M, Miller LD, Cao P, Maglic D, Zhang Q, Stampfer MR, Liu W, Xu J, Sui G. The regulation of SOX7 and its tumor suppressive role in breast cancer. Am J Pathol. 2013;183(5):1645-1653.

Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW. YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst. 2012;104(2):133-146.

Miller MS, Miller LD. RAS mutations and oncogenesis: not all RAS mutations are created equally. Front Genet. 2012;2():100.

Huang W, Smaldino PJ, Zhang Q, Miller LD, Cao P, Stadelman K, Wan M, Giri B, Lei M, Nagamine Y, Vaughn JP, Akman SA, Sui G. Yin Yang 1 contains G-quadruplex structures in its promoter and 5'-UTR and its expression is modulated by G4 resolvase 1. Nucleic Acids Res. 2012;40(3):1033-1049.

Wan M, Huang W, Kute TE, Miller LD, Zhang Q, Hatcher H, Wang J, Stovall DB, Russell GB, Cao PD, Deng Z, Wang W, Zhang Q, Lei M, Torti SV, Akman SA, Sui G. Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol. 2012;180(5):2120-2133.

Turner CP, Gutierrez S, Liu C, Miller L, Chou J, Finucane B, Carnes A, Kim J, Shing E, Haddad T, Phillips A. Strategies to defeat ketamine-induced neonatal brain injury. Neuroscience. 2012;210():384-392.

Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther. 2012;11(7):1488-1499.

Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol. 2012;23(11):2866-2873.

Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, Liu ET, Desai KV. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res. 2012;14(3):R85.

Lema Tome CM, Miller LD, Debinski W. Molecular and genetic features of highly migratory glioblastoma cells [abstract]. Neuro Oncol. 2012;14(Suppl 6):162.

Broet P, Dalmasso C, Tan EH, Alifano M, Zhang S, Wu J, Lee MH, Regnard J-F, Lim D, Miller LD, et al. Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin Cancer Res. 2011;17(11):3542-3550.

Ruiz J, Chou J, Geisinger KR, Schoppe CH, Miller AA, Willingham MC, Petty WJ, Bolemon BH, Miller LD. Microarray gene expression patterns recapitulated on a clinically tractable diagnostic platform using breast and lung cancer formalin-fixed paraffin-embedded tissues [abstract]. J Clin Oncol. 2011;29(Suppl):e21027.

Hou L, Arcury T, Quandt S, Miller L, Howard T, Grzywacz J, Miller J, Yalcinkaya TM. Use of spermatozoal mRNA profiles to study genes affected by pesticide exposure in humans [abstract]. Reprod Sci. 2011;18(4 Suppl):175A.

Soon WW, Miller LD, Black MA, Dalmasso C, Chan XB, Pang B, Ong CW, Salto-Tellez M, Desai KV, Liu ET. Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Mol Med. 2011;3(8):451-464.

Clausen KA, Blish KR, Birse CE, Triplette MA, Kute TE, Russell GB, D'Agostino RB Jr, Miller LD, Torti FM, Torti SV. SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Breast Cancer Res Treat. 2011;129(3):737-746.

Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R Jr, Torti SV, Torti FM. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res. 2011;71(21):6728-6737.

Kang J, Qian PX, Pandey V, Perry JK, Miller LD, Liu ET, Zhu T, Liu DX, Lobie PE. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. Oncogene. 2010;29(22):3228-3240.

Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010;2(43):43ra56.

Alifano M, Souaze F, Dupouy S, Camilleri-Broet S, Younes M, Ahmed-Zaid S-M, Takahashi T, Cancellieri A, Damiani S, Miller LD, et al. Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin Cancer Res. 2010;16(17):4401-4410.

Muthukaruppan A, Michael BA, Miller LD, Tamada Y, Allen TM, Woad KJ, Wang Y, Crampin EJ, Shelling AN, Print CG. The role of oestrogen signalling in breast cancer [abstract]. Ann Oncol. 2010;21(Suppl 4):54-55.

Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, Miller LD, Liu ET, Mertani HC, Zhu T, et al. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia. 2010;12(12):1041-1053.

Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010;9(12):3186-3199.

Ruiz J, Miller AA, Petty WJ, Chou JW, Miller LD. A novel prognostic transcriptional signature for early stage non-small cell lung cancer [abstract]. J Thorac Oncol. 2010;5(12 Suppl 7):S505.

Broet P, Camilleri-Broet S, Zhang S, Alifano M, Bangarusamy D, Battistella M, Wu Y, Tuefferd M, Regnard J-F, Miller LD, et al. Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. Cancer Res. 2009;69(3):1055-1062.

Zhang JQ, Liu XJ, Datta A, Govindarajan K, Tam WL, Han JY, George J, Wong C, Ramnarayanan K, Miller LD, et al. RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest. 2009;119(8):2171-2183.

Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen Y-T, Shin SJ, Jungbluth AA, Miller LD, Clouston D, Cebon J, et al. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A. 2009;106(32):13493-98.

Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin C-Y, Stanculescu A. Positive cross-talk between estrogen receptor and NF-kB in breast cancer. Cancer Res. 2009;69(23):8918-8925.

Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ, Jungbluth A, Miller LD, Cebon J, Old L, et al. Distinctive expression of cancer/testis-X antigens in a subset of ER negative breast carcinomas [abstract]. Cancer Res. 2009;69(24 Suppl 3):692S.

Yang X, Karuturi RKM, Sun F, Aau M, Yu K, Shao R, Miller LD, Tan PBO, Yu Q. CDKN1C (p57KIP2) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS ONE. 2009;4(4):e5011.

Cheung AKL, Lung HL, Hung SC, Law EWL, Cheng Y, Yau WL, Bangarusamy DK, Miller LD, Liu ET-B, Shao j-Y, et al. Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res. 2008;68(19):8137-8145.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Cancer Biology

Clinical Specialties

Cancer Cell Biology, Cancer Genetics, Breast Cancer

Quick Reference

Request an Appointment
New Patients


Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.